295 related articles for article (PubMed ID: 8635097)
1. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
[TBL] [Abstract][Full Text] [Related]
2. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
[TBL] [Abstract][Full Text] [Related]
3. Immunoscintigraphy using 111InCyt103 prior to second look laparotomy in ovarian cancer. A pilot study.
Hempling RE; Piver MS; Baker TR; Bakshi S; Gilani SS
Am J Clin Oncol; 1994 Aug; 17(4):331-4. PubMed ID: 8048395
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT.
Low RN; Carter WD; Saleh F; Sigeti JS
Radiology; 1995 May; 195(2):391-400. PubMed ID: 7724757
[TBL] [Abstract][Full Text] [Related]
5. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide.
Hinkle GH; Burgers JK; Neal CE; Texter JH; Kahn D; Williams RD; Maguire R; Rogers B; Olsen JO; Badalament RA
Cancer; 1998 Aug; 83(4):739-47. PubMed ID: 9708939
[TBL] [Abstract][Full Text] [Related]
6. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
Neal CE; Johnson DL; Cornwell VL; Markwell S
Clin Nucl Med; 1996 Aug; 21(8):638-42. PubMed ID: 8853918
[TBL] [Abstract][Full Text] [Related]
8. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?
Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP
Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800
[TBL] [Abstract][Full Text] [Related]
9. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
[TBL] [Abstract][Full Text] [Related]
10. [Value of radioimmunoscintigraphy compared to computed tomography in the diagnosis and follow-up of primary ovarian carcinoma].
Barzen G; Cordes M; Langer M; Friedman W; Mayr AC; Felix R
Rofo; 1990 Jul; 153(1):85-91. PubMed ID: 2166319
[TBL] [Abstract][Full Text] [Related]
11. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
Bohdiewicz PJ
J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434
[TBL] [Abstract][Full Text] [Related]
12. Results of immunoscintigraphy using a cocktail of radiolabeled monoclonal antibodies in the detection of colorectal cancer.
Volpe CM; Abdel-Nabi HH; Kulaylat MN; Doerr RJ
Ann Surg Oncol; 1998 Sep; 5(6):489-94. PubMed ID: 9754756
[TBL] [Abstract][Full Text] [Related]
13. Correlation of computed tomography with second-look laparotomy in ovarian carcinoma.
Sandhu M; Kumar L; Kumar S; Kriplani A; Bhatla N; Kinra G
Natl Med J India; 1996; 9(1):13-6. PubMed ID: 8713518
[TBL] [Abstract][Full Text] [Related]
14. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy.
Rose PG; Faulhaber P; Miraldi F; Abdul-Karim FW
Gynecol Oncol; 2001 Jul; 82(1):17-21. PubMed ID: 11426956
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma: a prospective study.
Crippa F; Presti M; Marini A; D'Onofrio B; Bolis G; Buraggi GL
Int J Biol Markers; 1990; 5(3):103-8. PubMed ID: 2286774
[TBL] [Abstract][Full Text] [Related]
16. [PET/CT scan with (18)F-FDG in re-staging of an atypical case of ovarian cancer].
García Gómez FJ; Cuenca Cuenca JI; Acevedo Báñez I; Borrego Dorado I; Calvo García E; Vázquez Albertino RJ
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):223-4. PubMed ID: 23067691
[No Abstract] [Full Text] [Related]
17. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
[TBL] [Abstract][Full Text] [Related]
18. Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma.
Lund B; Jacobsen K; Rasch L; Jensen F; Olesen K; Feldt-Rasmussen K
Gynecol Oncol; 1990 May; 37(2):279-83. PubMed ID: 2188880
[TBL] [Abstract][Full Text] [Related]
19. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
20. Impact of 111In-CYT-103 on the surgical management of patients with ovarian cancer.
Surwit EA
Targeted Diagn Ther; 1992; 6():125-40. PubMed ID: 1576343
[No Abstract] [Full Text] [Related]
[Next] [New Search]
